ID   UBP25_HUMAN             Reviewed;        1055 AA.
AC   Q9UHP3; C0LSZ0; Q6DHZ9; Q9H9W1;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   10-AUG-2010, sequence version 4.
DT   28-JUN-2023, entry version 205.
DE   RecName: Full=Ubiquitin carboxyl-terminal hydrolase 25;
DE            EC=3.4.19.12;
DE   AltName: Full=Deubiquitinating enzyme 25;
DE   AltName: Full=USP on chromosome 21;
DE   AltName: Full=Ubiquitin thioesterase 25;
DE   AltName: Full=Ubiquitin-specific-processing protease 25;
GN   Name=USP25; Synonyms=USP21;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS USP25A AND USP25B), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=10644437; DOI=10.1006/geno.1999.6025;
RA   Valero R., Marfany G., Gonzalez-Angulo O., Gonzalez-Gonzalez G.,
RA   Puelles L., Gonzalez-Duarte R.;
RT   "USP25, a novel gene encoding a deubiquitinating enzyme, is located in the
RT   gene-poor region 21q11.2.";
RL   Genomics 62:395-405(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM USP25A), AND FUNCTION.
RX   PubMed=10612803;
RX   DOI=10.1002/(sici)1098-2264(200002)27:2<153::aid-gcc6>3.3.co;2-1;
RA   Groet J., Ives J.H., Jones T.A., Danton M., Flomen R.H., Sheer D.,
RA   Hrascan R., Pavelic K., Nizetic D.;
RT   "Narrowing of the region of allelic loss in 21q11-21 in squamous non-small
RT   cell lung carcinoma and cloning of a novel ubiquitin-specific protease gene
RT   from the deleted segment.";
RL   Genes Chromosomes Cancer 27:153-161(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM USP25M).
RA   Valero R., Bosch-Comas A., Denuc A., Gonzalez-Duarte R., Marfany G.;
RL   Submitted (FEB-2009) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM USP25A).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 319-1055 (ISOFORM USP25A).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   ALTERNATIVE SPLICING, FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=11597335; DOI=10.1186/gb-2001-2-10-research0043;
RA   Valero R., Bayes M., Francisca Sanchez-Font M., Gonzalez-Angulo O.,
RA   Gonzalez-Duarte R., Marfany G.;
RT   "Characterization of alternatively spliced products and tissue-specific
RT   isoforms of USP28 and USP25.";
RL   Genome Biol. 2:RESEARCH0043.1-RESEARCH0043.10(2001).
RN   [8]
RP   ALTERNATIVE SPLICING, INTERACTION WITH ACTA1; FLNC; GAPDH AND MYBPC1,
RP   INDUCTION, SUBCELLULAR LOCATION, AND POSSIBLE FUNCTION.
RX   PubMed=16501887; DOI=10.1007/s00018-005-5533-1;
RA   Bosch-Comas A., Lindsten K., Gonzalez-Duarte R., Masucci M.G., Marfany G.;
RT   "The ubiquitin-specific protease USP25 interacts with three sarcomeric
RT   proteins.";
RL   Cell. Mol. Life Sci. 63:723-734(2006).
RN   [9]
RP   SUMOYLATION AT LYS-99, FUNCTION, INTERACTION WITH SUMO1; SUMO3 AND
RP   UBIQUITIN, IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF VAL-91;
RP   ILE-92 AND LYS-99.
RX   PubMed=18538659; DOI=10.1016/j.molcel.2008.03.021;
RA   Meulmeester E., Kunze M., Hsiao H.H., Urlaub H., Melchior F.;
RT   "Mechanism and consequences for paralog-specific sumoylation of ubiquitin-
RT   specific protease 25.";
RL   Mol. Cell 30:610-619(2008).
RN   [10]
RP   UBIQUITINATION AT LYS-99, DEUBIQUITINATION, ACTIVE SITE CYS-178,
RP   ACETYLATION, PHOSPHORYLATION, SUMOYLATION, FUNCTION, SUBCELLULAR LOCATION,
RP   SUBUNIT, AND MUTAGENESIS OF LYS-99 AND CYS-178.
RX   PubMed=19440361; DOI=10.1371/journal.pone.0005571;
RA   Denuc A., Bosch-Comas A., Gonzalez-Duarte R., Marfany G.;
RT   "The UBA-UIM domains of the USP25 regulate the enzyme ubiquitination state
RT   and modulate substrate recognition.";
RL   PLoS ONE 4:E5571-E5571(2009).
RN   [11]
RP   INTERACTION WITH SYK, PHOSPHORYLATION AT TYR-740, AND MUTAGENESIS OF
RP   TYR-740; THR-878; TYR-880 AND ILE-883.
RX   PubMed=19909739; DOI=10.1016/j.yexcr.2009.10.023;
RA   Cholay M., Reverdy C., Benarous R., Colland F., Daviet L.;
RT   "Functional interaction between the ubiquitin-specific protease 25 and the
RT   SYK tyrosine kinase.";
RL   Exp. Cell Res. 316:667-675(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-85, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
CC   -!- FUNCTION: Deubiquitinating enzyme that hydrolyzes ubiquitin moieties
CC       conjugated to substrates and thus, functions to process newly
CC       synthesized Ubiquitin, to recycle ubiquitin molecules or to edit
CC       polyubiquitin chains and prevents proteasomal degradation of
CC       substrates. Hydrolyzes both 'Lys-48'- and 'Lys-63'-linked
CC       tetraubiquitin chains.
CC   -!- FUNCTION: The muscle-specific isoform (USP25m) may have a role in the
CC       regulation of muscular differentiation and function.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12;
CC   -!- SUBUNIT: Homodimer or oligomer. Interacts with ACTA1 (via its C-
CC       terminus); the interaction occurs for all isoforms but is strongest for
CC       isoform USP25m in muscle differentiating cells. Interacts (isoform
CC       USP25m only) with MYBPC1; the interaction prevents proteasomal
CC       degradation of MYBPC1. Interacts (isoform USP25m only) with FLNC (via
CC       filament repeats 17-18, 20-21 and 24). Interacts with GAPDH. Interacts
CC       with SUMO3; the interaction sumoylates efficiently USP25. Interacts
CC       with SUMO2; the interaction sumoylates efficiently USP25. Interacts
CC       with SUMO1; the interaction only weakly sumoylates USP25. Interacts
CC       with SYK; phosphorylates USP25 and regulates USP25 intracellular
CC       levels. {ECO:0000269|PubMed:16501887, ECO:0000269|PubMed:18538659,
CC       ECO:0000269|PubMed:19440361, ECO:0000269|PubMed:19909739}.
CC   -!- INTERACTION:
CC       Q9UHP3; O15481: MAGEB4; NbExp=3; IntAct=EBI-2513462, EBI-751857;
CC       Q9UHP3; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-2513462, EBI-10172526;
CC       Q9UHP3; P17612: PRKACA; NbExp=3; IntAct=EBI-2513462, EBI-476586;
CC       Q9UHP3; Q3MIT2: PUS10; NbExp=3; IntAct=EBI-2513462, EBI-11983583;
CC       Q9UHP3; P54725: RAD23A; NbExp=12; IntAct=EBI-2513462, EBI-746453;
CC       Q9UHP3; P54727: RAD23B; NbExp=4; IntAct=EBI-2513462, EBI-954531;
CC       Q9UHP3; P61956: SUMO2; NbExp=6; IntAct=EBI-2513462, EBI-473220;
CC       Q9UHP3; P43405: SYK; NbExp=8; IntAct=EBI-2513462, EBI-78302;
CC       Q9UHP3; P37173: TGFBR2; NbExp=3; IntAct=EBI-2513462, EBI-296151;
CC       Q9UHP3; Q9BTV4: TMEM43; NbExp=3; IntAct=EBI-2513462, EBI-721293;
CC       Q9UHP3; Q9BUY5: ZNF426; NbExp=3; IntAct=EBI-2513462, EBI-743265;
CC       Q9UHP3; PRO_0000449633 [P0DTD1]: rep; Xeno; NbExp=6; IntAct=EBI-2513462, EBI-25492395;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16501887,
CC       ECO:0000269|PubMed:19440361}.
CC   -!- SUBCELLULAR LOCATION: [Isoform USP25m]: Cytoplasm {ECO:0000250}.
CC       Nucleus {ECO:0000250}. Note=Some transient punctuate nuclear location
CC       in myotubes during myocyte development. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=USP25a;
CC         IsoId=Q9UHP3-2; Sequence=Displayed;
CC       Name=USP25b;
CC         IsoId=Q9UHP3-1; Sequence=VSP_039632;
CC       Name=USP25m; Synonyms=Muscle-specific isoform;
CC         IsoId=Q9UHP3-3; Sequence=VSP_039631;
CC   -!- TISSUE SPECIFICITY: Isoform USP25a is found in most adult and fetal
CC       tissues; expression is moderately high in testis, pancreas, kidney,
CC       skeletal muscle, liver, lung, placenta, brain, heart, but very low in
CC       peripheral blood, colon, small intestine, ovary, prostate, thymus and
CC       spleen. Isoform USP25b is found in all tissues except heart and
CC       skeletal muscle. Isoform USP25m is heart and skeletal muscle specific.
CC       {ECO:0000269|PubMed:10644437, ECO:0000269|PubMed:11597335}.
CC   -!- INDUCTION: The muscle-specific isoform (USP25m) is up-regulated during
CC       myocyte differentiation. Levels increase up to 100-fold towards
CC       completion of differentiation. {ECO:0000269|PubMed:16501887}.
CC   -!- PTM: Acetylated. {ECO:0000269|PubMed:19440361}.
CC   -!- PTM: Sumoylation impairs binding to and hydrolysis of ubiquitin chains.
CC       Sumoylated preferentially with SUMO2 or SUMO3. Desumoylated by SENP1.
CC       Regulated by ubiquitination on the same residue.
CC       {ECO:0000269|PubMed:19440361}.
CC   -!- PTM: Preferentially monoubiquitinated but can also be
CC       polyubiquitinated. Autodeubiquitinated. Ubiquitination activates the
CC       enzymatic activity either by preventing sumoylation or by allowing
CC       novel interactions. {ECO:0000269|PubMed:19440361}.
CC   -!- PTM: Phosphorylation in the C-terminal by SYK regulates USP25 cellular
CC       levels. {ECO:0000269|PubMed:19440361, ECO:0000269|PubMed:19909739}.
CC   -!- SIMILARITY: Belongs to the peptidase C19 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF170562; AAF32263.1; -; mRNA.
DR   EMBL; AF134213; AAF24998.1; -; mRNA.
DR   EMBL; FJ763652; ACN76567.1; -; mRNA.
DR   EMBL; CH471079; EAX10041.1; -; Genomic_DNA.
DR   EMBL; BC075792; AAH75792.1; -; mRNA.
DR   EMBL; AK022574; BAB14107.1; -; mRNA.
DR   CCDS; CCDS33515.1; -. [Q9UHP3-2]
DR   CCDS; CCDS63336.1; -. [Q9UHP3-3]
DR   CCDS; CCDS63337.1; -. [Q9UHP3-1]
DR   RefSeq; NP_001269970.1; NM_001283041.1. [Q9UHP3-3]
DR   RefSeq; NP_001269971.1; NM_001283042.1. [Q9UHP3-1]
DR   RefSeq; NP_037528.3; NM_013396.4. [Q9UHP3-2]
DR   PDB; 2MUX; NMR; -; A=1-146.
DR   PDB; 5GP7; X-ray; 1.50 A; B=1046-1055.
DR   PDB; 5O71; X-ray; 3.28 A; A=1-714.
DR   PDB; 6H4J; X-ray; 3.07 A; A/B=157-706.
DR   PDB; 6H4K; X-ray; 2.05 A; A=765-1055.
DR   PDB; 6HEL; X-ray; 2.94 A; A/B=157-714.
DR   PDB; 6HEM; X-ray; 1.72 A; A=748-1048.
DR   PDBsum; 2MUX; -.
DR   PDBsum; 5GP7; -.
DR   PDBsum; 5O71; -.
DR   PDBsum; 6H4J; -.
DR   PDBsum; 6H4K; -.
DR   PDBsum; 6HEL; -.
DR   PDBsum; 6HEM; -.
DR   AlphaFoldDB; Q9UHP3; -.
DR   BMRB; Q9UHP3; -.
DR   SMR; Q9UHP3; -.
DR   BioGRID; 118895; 92.
DR   IntAct; Q9UHP3; 40.
DR   MINT; Q9UHP3; -.
DR   STRING; 9606.ENSP00000383044; -.
DR   BindingDB; Q9UHP3; -.
DR   ChEMBL; CHEMBL4295975; -.
DR   MEROPS; C19.041; -.
DR   iPTMnet; Q9UHP3; -.
DR   PhosphoSitePlus; Q9UHP3; -.
DR   BioMuta; USP25; -.
DR   DMDM; 302393833; -.
DR   EPD; Q9UHP3; -.
DR   jPOST; Q9UHP3; -.
DR   MassIVE; Q9UHP3; -.
DR   MaxQB; Q9UHP3; -.
DR   PaxDb; Q9UHP3; -.
DR   PeptideAtlas; Q9UHP3; -.
DR   ProteomicsDB; 84385; -. [Q9UHP3-2]
DR   ProteomicsDB; 84386; -. [Q9UHP3-1]
DR   ProteomicsDB; 84387; -. [Q9UHP3-3]
DR   Antibodypedia; 5805; 284 antibodies from 30 providers.
DR   DNASU; 29761; -.
DR   Ensembl; ENST00000285679.10; ENSP00000285679.6; ENSG00000155313.16. [Q9UHP3-2]
DR   Ensembl; ENST00000285681.6; ENSP00000285681.2; ENSG00000155313.16. [Q9UHP3-1]
DR   Ensembl; ENST00000400183.7; ENSP00000383044.2; ENSG00000155313.16. [Q9UHP3-3]
DR   GeneID; 29761; -.
DR   KEGG; hsa:29761; -.
DR   MANE-Select; ENST00000400183.7; ENSP00000383044.2; NM_001283041.3; NP_001269970.1. [Q9UHP3-3]
DR   UCSC; uc002yjy.3; human. [Q9UHP3-2]
DR   AGR; HGNC:12624; -.
DR   CTD; 29761; -.
DR   DisGeNET; 29761; -.
DR   GeneCards; USP25; -.
DR   HGNC; HGNC:12624; USP25.
DR   HPA; ENSG00000155313; Tissue enhanced (skeletal).
DR   MIM; 604736; gene.
DR   neXtProt; NX_Q9UHP3; -.
DR   OpenTargets; ENSG00000155313; -.
DR   PharmGKB; PA37249; -.
DR   VEuPathDB; HostDB:ENSG00000155313; -.
DR   eggNOG; KOG1863; Eukaryota.
DR   GeneTree; ENSGT00940000157962; -.
DR   HOGENOM; CLU_012188_0_0_1; -.
DR   InParanoid; Q9UHP3; -.
DR   OMA; XKKFENT; -.
DR   OrthoDB; 1423057at2759; -.
DR   PhylomeDB; Q9UHP3; -.
DR   TreeFam; TF329035; -.
DR   PathwayCommons; Q9UHP3; -.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   SignaLink; Q9UHP3; -.
DR   BioGRID-ORCS; 29761; 12 hits in 1206 CRISPR screens.
DR   ChiTaRS; USP25; human.
DR   GenomeRNAi; 29761; -.
DR   Pharos; Q9UHP3; Tchem.
DR   PRO; PR:Q9UHP3; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   RNAct; Q9UHP3; protein.
DR   Bgee; ENSG00000155313; Expressed in sperm and 198 other tissues.
DR   ExpressionAtlas; Q9UHP3; baseline and differential.
DR   Genevisible; Q9UHP3; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0051117; F:ATPase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0004843; F:cysteine-type deubiquitinase activity; IMP:UniProtKB.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IBA:GO_Central.
DR   GO; GO:0008233; F:peptidase activity; TAS:ProtInc.
DR   GO; GO:0032183; F:SUMO binding; IPI:UniProtKB.
DR   GO; GO:0043130; F:ubiquitin binding; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0019783; F:ubiquitin-like protein peptidase activity; NAS:ParkinsonsUK-UCL.
DR   GO; GO:1904293; P:negative regulation of ERAD pathway; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0016579; P:protein deubiquitination; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0071108; P:protein K48-linked deubiquitination; IMP:UniProtKB.
DR   GO; GO:0070536; P:protein K63-linked deubiquitination; IMP:UniProtKB.
DR   GO; GO:0036211; P:protein modification process; TAS:ProtInc.
DR   GO; GO:0006508; P:proteolysis; TAS:ProtInc.
DR   GO; GO:0031647; P:regulation of protein stability; IBA:GO_Central.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   CDD; cd02665; Peptidase_C19I; 1.
DR   CDD; cd14354; UBA_UBP25; 1.
DR   CDD; cd20486; USP25_C; 1.
DR   Gene3D; 6.10.250.1720; -; 1.
DR   Gene3D; 3.90.70.10; Cysteine proteinases; 1.
DR   Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1.
DR   InterPro; IPR038765; Papain-like_cys_pep_sf.
DR   InterPro; IPR001394; Peptidase_C19_UCH.
DR   InterPro; IPR009060; UBA-like_sf.
DR   InterPro; IPR003903; UIM_dom.
DR   InterPro; IPR018200; USP_CS.
DR   InterPro; IPR028889; USP_dom.
DR   PANTHER; PTHR24006; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE; 1.
DR   PANTHER; PTHR24006:SF666; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE 25; 1.
DR   Pfam; PF00443; UCH; 1.
DR   Pfam; PF02809; UIM; 2.
DR   SMART; SM00726; UIM; 1.
DR   SUPFAM; SSF54001; Cysteine proteinases; 1.
DR   SUPFAM; SSF46934; UBA-like; 1.
DR   PROSITE; PS50330; UIM; 1.
DR   PROSITE; PS00972; USP_1; 1.
DR   PROSITE; PS00973; USP_2; 1.
DR   PROSITE; PS50235; USP_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Coiled coil; Cytoplasm; Hydrolase;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Protease; Reference proteome;
KW   Repeat; Thiol protease; Ubl conjugation; Ubl conjugation pathway.
FT   CHAIN           1..1055
FT                   /note="Ubiquitin carboxyl-terminal hydrolase 25"
FT                   /id="PRO_0000080653"
FT   DOMAIN          14..57
FT                   /note="UBA-like"
FT   DOMAIN          97..116
FT                   /note="UIM 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00213"
FT   DOMAIN          123..140
FT                   /note="UIM 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00213"
FT   DOMAIN          169..657
FT                   /note="USP"
FT   REGION          77..102
FT                   /note="SUMO interaction domain (SIM)"
FT   REGION          464..507
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          727..749
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          541..578
FT                   /evidence="ECO:0000255"
FT   COILED          684..717
FT                   /evidence="ECO:0000255"
FT   MOTIF           89..95
FT                   /note="Required for SUMO paralog-specific binding"
FT   COMPBIAS        472..507
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        178
FT                   /evidence="ECO:0000269|PubMed:19440361"
FT   ACT_SITE        599
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        607
FT                   /evidence="ECO:0000250"
FT   MOD_RES         85
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         740
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:19909739"
FT   CROSSLNK        99
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT   CROSSLNK        99
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000269|PubMed:19440361"
FT   VAR_SEQ         779
FT                   /note="S -> SIMMTPNMQGIIMAIGKSRSVYDRCGPEAGFFK (in isoform
FT                   USP25b)"
FT                   /evidence="ECO:0000303|PubMed:10644437"
FT                   /id="VSP_039632"
FT   VAR_SEQ         779
FT                   /note="S -> SKPENTTSQPLSNQRVVEVAIPHVGKFMIESKEGGYDDEIMMTPNMQ
FT                   GIIMAIGKSRSVYDRCGPEAGFFK (in isoform USP25m)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_039631"
FT   MUTAGEN         91
FT                   /note="V->A: No interaction with SUMO3; when associated
FT                   with A-92."
FT                   /evidence="ECO:0000269|PubMed:18538659"
FT   MUTAGEN         92
FT                   /note="I->A: No interaction with SUMO3; when associated
FT                   with A-91."
FT                   /evidence="ECO:0000269|PubMed:18538659"
FT   MUTAGEN         99
FT                   /note="K->R: Abolishes sumoylation. Decreased enzymatic
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:18538659,
FT                   ECO:0000269|PubMed:19440361"
FT   MUTAGEN         178
FT                   /note="C->S: Abrogates deubiquitinating activity. No effect
FT                   on homo- or oligomerization."
FT                   /evidence="ECO:0000269|PubMed:19440361"
FT   MUTAGEN         740
FT                   /note="Y->F: No effect on interaction with SYK."
FT                   /evidence="ECO:0000269|PubMed:19909739"
FT   MUTAGEN         878
FT                   /note="T->I: No effect on interaction with SYK."
FT                   /evidence="ECO:0000269|PubMed:19909739"
FT   MUTAGEN         880
FT                   /note="Y->F: No effect on interaction with SYK."
FT                   /evidence="ECO:0000269|PubMed:19909739"
FT   MUTAGEN         883
FT                   /note="I->S: No effect on interaction with SYK."
FT                   /evidence="ECO:0000269|PubMed:19909739"
FT   CONFLICT        544
FT                   /note="E -> K (in Ref. 1; AAF32263 and 3; ACN76567)"
FT                   /evidence="ECO:0000305"
FT   HELIX           12..27
FT                   /evidence="ECO:0007829|PDB:2MUX"
FT   HELIX           33..43
FT                   /evidence="ECO:0007829|PDB:2MUX"
FT   HELIX           47..55
FT                   /evidence="ECO:0007829|PDB:2MUX"
FT   STRAND          61..64
FT                   /evidence="ECO:0007829|PDB:2MUX"
FT   STRAND          69..71
FT                   /evidence="ECO:0007829|PDB:2MUX"
FT   HELIX           100..116
FT                   /evidence="ECO:0007829|PDB:2MUX"
FT   HELIX           125..136
FT                   /evidence="ECO:0007829|PDB:2MUX"
FT   TURN            158..161
FT                   /evidence="ECO:0007829|PDB:6H4J"
FT   STRAND          164..166
FT                   /evidence="ECO:0007829|PDB:5O71"
FT   TURN            174..176
FT                   /evidence="ECO:0007829|PDB:6H4J"
FT   HELIX           178..189
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   HELIX           191..198
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   HELIX           218..234
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          237..240
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   HELIX           243..248
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   HELIX           263..279
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   HELIX           283..285
FT                   /evidence="ECO:0007829|PDB:5O71"
FT   HELIX           294..299
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          302..304
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          309..311
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          321..326
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   HELIX           333..342
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          348..350
FT                   /evidence="ECO:0007829|PDB:6H4J"
FT   TURN            351..355
FT                   /evidence="ECO:0007829|PDB:6H4J"
FT   STRAND          362..365
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          368..375
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          377..380
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   TURN            381..384
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          385..388
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          397..400
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   TURN            402..404
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   HELIX           406..408
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   HELIX           409..437
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          441..444
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   HELIX           448..460
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          534..536
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   HELIX           542..579
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   HELIX           584..586
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          590..601
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          603..614
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   TURN            615..618
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          619..624
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          627..629
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   HELIX           633..640
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          641..644
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   STRAND          648..658
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   HELIX           660..662
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   TURN            669..671
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   HELIX           677..680
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   HELIX           683..700
FT                   /evidence="ECO:0007829|PDB:6HEL"
FT   HELIX           751..765
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   HELIX           773..793
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   HELIX           802..804
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   HELIX           807..813
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   HELIX           818..829
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   HELIX           832..834
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   STRAND          835..837
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   TURN            838..840
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   HELIX           841..853
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   TURN            856..858
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   HELIX           861..889
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   HELIX           893..913
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   HELIX           921..943
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   HELIX           948..960
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   HELIX           962..965
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   HELIX           966..970
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   HELIX           976..990
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   HELIX           991..994
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   HELIX           999..1013
FT                   /evidence="ECO:0007829|PDB:6HEM"
FT   HELIX           1033..1044
FT                   /evidence="ECO:0007829|PDB:6HEM"
SQ   SEQUENCE   1055 AA;  122218 MW;  0B9CECDCAD619CF2 CRC64;
     MTVEQNVLQQ SAAQKHQQTF LNQLREITGI NDTQILQQAL KDSNGNLELA VAFLTAKNAK
     TPQQEETTYY QTALPGNDRY ISVGSQADTN VIDLTGDDKD DLQRAIALSL AESNRAFRET
     GITDEEQAIS RVLEASIAEN KACLKRTPTE VWRDSRNPYD RKRQDKAPVG LKNVGNTCWF
     SAVIQSLFNL LEFRRLVLNY KPPSNAQDLP RNQKEHRNLP FMRELRYLFA LLVGTKRKYV
     DPSRAVEILK DAFKSNDSQQ QDVSEFTHKL LDWLEDAFQM KAEEETDEEK PKNPMVELFY
     GRFLAVGVLE GKKFENTEMF GQYPLQVNGF KDLHECLEAA MIEGEIESLH SENSGKSGQE
     HWFTELPPVL TFELSRFEFN QALGRPEKIH NKLEFPQVLY LDRYMHRNRE ITRIKREEIK
     RLKDYLTVLQ QRLERYLSYG SGPKRFPLVD VLQYALEFAS SKPVCTSPVD DIDASSPPSG
     SIPSQTLPST TEQQGALSSE LPSTSPSSVA AISSRSVIHK PFTQSRIPPD LPMHPAPRHI
     TEEELSVLES CLHRWRTEIE NDTRDLQESI SRIHRTIELM YSDKSMIQVP YRLHAVLVHE
     GQANAGHYWA YIFDHRESRW MKYNDIAVTK SSWEELVRDS FGGYRNASAY CLMYINDKAQ
     FLIQEEFNKE TGQPLVGIET LPPDLRDFVE EDNQRFEKEL EEWDAQLAQK ALQEKLLASQ
     KLRESETSVT TAQAAGDPEY LEQPSRSDFS KHLKEETIQI ITKASHEHED KSPETVLQSA
     IKLEYARLVK LAQEDTPPET DYRLHHVVVY FIQNQAPKKI IEKTLLEQFG DRNLSFDERC
     HNIMKVAQAK LEMIKPEEVN LEEYEEWHQD YRKFRETTMY LIIGLENFQR ESYIDSLLFL
     ICAYQNNKEL LSKGLYRGHD EELISHYRRE CLLKLNEQAA ELFESGEDRE VNNGLIIMNE
     FIVPFLPLLL VDEMEEKDIL AVEDMRNRWC SYLGQEMEPH LQEKLTDFLP KLLDCSMEIK
     SFHEPPKLPS YSTHELCERF ARIMLSLSRT PADGR
//
